Piramal Enterprises’ Pharma Solutions Division Receives Two Coveted CMO Leadership Awards (2013) for “Quality” and “Reliability”

April 7, 2014

BOSTON, April 7, 2014 /PRNewswire/ –

Piramal Enterprises’ Pharma Solutions Division, a global pharmaceutical contract
development and manufacturing organization (CDMO), has received CMO Leadership Awards 2013
in two categories – Quality and Reliability, at a prestigious ceremony at DCAT in New
York. Within the Reliability category, Piramal has been recognized as the most “Reliable”
CMO among the 5 CMOs shortlisted for this award.

http://photos.prnewswire.com/prnh/20130724/629310 )

The CMO Leadership Awards are given by Life Science Leader based on the
industry-leading research conducted by Nice Insight. They survey over 11,000 buyers of
outsourced services annually to determine perception and awareness scores of CMOs for five
different attributes (i.e. Innovation, Productivity, Quality, Regulatory, and
Reliability). Companies achieving top 20 percentile perception scores across these 5
attributes are recognized for their achievement.

The annual award recognizes those contract manufacturing organizations (CMOs) that are
the most highly rated by industry respondents. Unlike other industry awards, which are
given based on a subjective voting or nomination process, the only votes that count
towards the CRO/CMO Leadership Awards are those of the pharmaceutical and
biopharmaceutical companies using CRO/CMO services.

Mr. Vivek Sharma, CEO – Pharma Solutions & Critical Care Division, Piramal Enterprises
Ltd said, “These awards are a representation of our work which all our sites have been
implementing for our customers. This recognition is a huge achievement for us and a step
forward in our mission to move towards “Customer Centricity”. Being Customer Centric is
not just about asking what the customer wants, it is about reading signs, pre-empting
expectations and going beyond what is an obvious choice.”

Piramal Pharma Solutions is known for its capabilities as an integrated solutions
provider, offering a comprehensive range of services across the drug lifecycle. It has a
successful performance record of over 40 years for the supply of APIs and Drug Products
and Drug Discovery services to the US and European markets from its facilities located in
North America, Europe and India. Niche technologies such as Biocatalysis & Advanced Flow
Reactors (AFR) are an area of focus to support our customers to develop cost-competitive

Significant investments in new technologies and capacity expansions have been made
recently such as upgrading the US FDA approved Grangemouth, UK, ADC manufacturing facility
with an investment of USD 2.5 million. Furthermore, Piramal is investing 11 million USD at
its Morpeth, UK facility to triple the production capacity for hormonal products.

About Piramal Enterprises Ltd:

Piramal Enterprises (PEL) is one of India’s largest diversified companies, with a
presence in pharmaceuticals, financial services and healthcare information management
sectors. PEL had consolidated revenues of over $650 million in FY2013. In the
pharmaceutical space, PEL is one of the leading Contract Development and Manufacturing
organizations globally, and has a strong presence in the global critical care segment with
a portfolio of inhalation and injectable anesthetics. Its OTC business is ranked no. 7 in
India. PEL is also engaged in drug discovery and research, and has a strong pipeline of
development products. In the financial services space, PEL has a real estate focused PE
fund – Indiareit, and a NBFC that is focused on lending to the real estate and education
sectors. PEL’s healthcare information management business, Decision Resources Group, is a
leading provider of information-based services to the healthcare industry.

        For Media Queries:
        Akansha Pradhan / Riddhi Goradia
        Corporate Communications,
        Piramal Group
        Contact: +91-22-3351-4082/4083



SOURCE Piramal Enterprises Ltd

Source: PR Newswire

comments powered by Disqus